Press "Enter" to skip to content

New patent for Celgene drug POMALYST

2
Copyright © DrugPatentWatch. Originally published at New patent for Celgene drug POMALYST

Annual Drug Patent Expirations for POMALYST
Annual Drug Patent Expirations for POMALYST

Pomalyst is a drug marketed by Celgene and is included in one NDA. It is available from one supplier. There are eleven patents protecting this drug and one Paragraph IV challenge.

Drug patent litigation for POMALYST.

This drug has three hundred and thirty-nine patent family members in forty-seven countries.

The generic ingredient in POMALYST is pomalidomide. One supplier is listed for this compound. Additional details are available on the pomalidomide profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com

Make Better Decisions with DrugPatentWatch

Get the Daily Briefing or Try a trial

Copyright © DrugPatentWatch. Originally published at New patent for Celgene drug POMALYST

Comments are closed.

Get the DrugPatentWatch Daily Briefing

✓ Patent Expirations and Generic Entry

✓ Insightful Articles & Case Studies

✓ Patent Litigation & Challenges

✓ 505(b)(2) & Biosimilars

✓ Industry Trends

Do NOT follow this link or you will be banned from the site!